<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/ka.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
	<script type="text/javascript" charset="utf-8">
	var ANIMATION = [
		custom('.charttabwrap','display: block !important;'),'q'
		/*	".charttabwrap",
			mask(".ln_2"),
			mask(".ln_1")*/
		];
	</script>
</head>
<body class="slide-22"><div id="main"><div id="content"> <div class="whiteoverlay"></div> <div id="logo"><img src="images/blkAbbott_logo.png" width="154" height="52" alt="Abbott"></div> <h1>Time to confirmed virologic failure by treatment group<sup>2</sup></h1> <div class="charttabwrap" style="display:none;"> <div id="leftchart" class="frame-1" onclick="makecall('PopupMessageHTML',Array('ka-22-chart-01','virologic failure Chart 1','450','365','0','0','830','570'));"> <div class="ln_1"><!-- <img src="images/3h_Efficacy_A_ART.png" width="547" height="421"> --> </div> <div class="ln_2"><!-- <img src="images/3h_Efficacy_A_KAL.png" width="547" height="421"> --> </div> </div><div id="leftchart-2" class="frame-2" onclick="makecall('PopupMessageHTML',Array('ka-22-chart-02','virologic failure Chart 2','450','365','0','0','830','570'));"> <div class="ln_1"><!-- <img src="images/3i_Efficacy_A_ART.png" width="547" height="421"> --> </div> <div class="ln_2"><!-- <img src="images/3i_Efficacy_A_KAL.png" width="547" height="421"> --> </div> </div> <div class="switch_tabwrap"> <div class="tab dot active" ontouchend="animateTo(0);"><a href="#">SWITCHMRK 1</a></div> <div class="tab dot" ontouchend="animateTo(0);"><a href="#">SWITCHMRK 2</a></div> </div> </div> <div id="rightcol"> <div class="blk_bullet">Time to virological failure was defined as the time on study until the first of 2 consecutive vRNA concentrations of 50 copies/mL or more measured at least 1 week apart.</div> <div class="blk_bullet">Time to confirmed virological failure was similar for the raltegravir and KALETRA groups in SWITCHMRK 1 (log-rank test, <em>P</em>=0.5023), whereas it was shorter for patients in the raltegravir group than for those in the KALETRA group in SWITCHMRK 2 (log-rank test, <em>P</em>=0.0136).</div><div class="smallcap">*Kaplan-Meier estimates were computed for time to virologic failure for each treatment group. All available samples obtained up to the date when the last patient completed the visit at week 24 were included in the analysis. The numbers below the x-axis give the number of participants contributing to the analysis at each timepoint.</div> </div> <div class="btns"> <div class="studybtn"><a href="#"><img src="images/Button-StudyDesignA.png" width="132" height="42" alt="Study Design" ontouchend="makecall('PopupMessageHTMLWithTopnav',Array('ka-19-popup-01','<DIV align=\'left\'><font color=\'white\' face=\'Helvetica\'><p ><strong>}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}Study Design</strong></p></font></DIV>','780','670','10','0','575','460'));"></a></div> <div class="baselinebtn"><a href="#"><img src="images/Button-Baseline_A.png" width="132" height="42" alt="Baseline Values" ontouchend="makecall('PopupMessageHTMLWithTopnav',Array('ka-19-popup-02','<DIV align=\'left\'><font color=\'white\' face=\'Helvetica\'><p ><strong>}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}Baseline Values</strong></p></font></DIV>','920','670','10','0','580','350'));"></a></div> </div> <div id="footer"> <p>Please click buttons above for indication<br>and Important Safety Information about KALETRA.</p> </div> </div></div></body></html>